vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Enpro Inc. (NPO). Click either name above to swap in a different company.
Enpro Inc. is the larger business by last-quarter revenue ($295.4M vs $247.1M, roughly 1.2× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -10.8%, a 22.0% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 14.3%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 7.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Enpro is a US-based industrial technology company that designs and manufactures products and materials for technology-intensive sectors. The company serves industries such as semiconductors, aerospace, power generation, heavy-duty trucking, agricultural machinery, chemical processing, pulp and paper, and life sciences from 61 primary manufacturing facilities located in 12 countries, worldwide. It is organized under three segments: Sealing Technologies, Advanced Surface Technologies, and Engin...
ANIP vs NPO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $295.4M |
| Net Profit | $27.5M | $-32.0M |
| Gross Margin | — | 42.1% |
| Operating Margin | 14.1% | 11.2% |
| Net Margin | 11.1% | -10.8% |
| Revenue YoY | 29.6% | 14.3% |
| Net Profit YoY | 367.5% | -330.2% |
| EPS (diluted) | $1.14 | $-1.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $295.4M | ||
| Q3 25 | $227.8M | $286.6M | ||
| Q2 25 | $211.4M | $288.1M | ||
| Q1 25 | $197.1M | $273.2M | ||
| Q4 24 | $190.6M | $258.4M | ||
| Q3 24 | $148.3M | $260.9M | ||
| Q2 24 | $138.0M | $271.9M | ||
| Q1 24 | $137.4M | $257.5M |
| Q4 25 | $27.5M | $-32.0M | ||
| Q3 25 | $26.6M | $21.6M | ||
| Q2 25 | $8.5M | $26.4M | ||
| Q1 25 | $15.7M | $24.5M | ||
| Q4 24 | $-10.3M | $13.9M | ||
| Q3 24 | $-24.2M | $19.8M | ||
| Q2 24 | $-2.3M | $26.7M | ||
| Q1 24 | $18.2M | $12.5M |
| Q4 25 | — | 42.1% | ||
| Q3 25 | — | 41.9% | ||
| Q2 25 | — | 43.3% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 42.3% | ||
| Q3 24 | — | 42.3% | ||
| Q2 24 | — | 43.8% | ||
| Q1 24 | — | 41.2% |
| Q4 25 | 14.1% | 11.2% | ||
| Q3 25 | 15.9% | 14.3% | ||
| Q2 25 | 6.6% | 15.9% | ||
| Q1 25 | 13.3% | 15.3% | ||
| Q4 24 | -2.3% | 12.5% | ||
| Q3 24 | -13.8% | 13.1% | ||
| Q2 24 | 3.7% | 17.7% | ||
| Q1 24 | 14.8% | 10.9% |
| Q4 25 | 11.1% | -10.8% | ||
| Q3 25 | 11.7% | 7.5% | ||
| Q2 25 | 4.0% | 9.2% | ||
| Q1 25 | 8.0% | 9.0% | ||
| Q4 24 | -5.4% | 5.4% | ||
| Q3 24 | -16.3% | 7.6% | ||
| Q2 24 | -1.7% | 9.8% | ||
| Q1 24 | 13.2% | 4.9% |
| Q4 25 | $1.14 | $-1.50 | ||
| Q3 25 | $1.13 | $1.01 | ||
| Q2 25 | $0.36 | $1.25 | ||
| Q1 25 | $0.69 | $1.15 | ||
| Q4 24 | $-0.45 | $0.65 | ||
| Q3 24 | $-1.27 | $0.94 | ||
| Q2 24 | $-0.14 | $1.27 | ||
| Q1 24 | $0.82 | $0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $114.7M |
| Total DebtLower is stronger | — | $655.3M |
| Stockholders' EquityBook value | $540.7M | $1.5B |
| Total Assets | $1.4B | $2.7B |
| Debt / EquityLower = less leverage | — | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $114.7M | ||
| Q3 25 | $262.6M | $132.9M | ||
| Q2 25 | $217.8M | $107.1M | ||
| Q1 25 | $149.8M | $240.3M | ||
| Q4 24 | $144.9M | $236.3M | ||
| Q3 24 | $145.0M | $206.9M | ||
| Q2 24 | $240.1M | $175.9M | ||
| Q1 24 | $228.6M | $163.9M |
| Q4 25 | — | $655.3M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $640.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $644.9M |
| Q4 25 | $540.7M | $1.5B | ||
| Q3 25 | $505.8M | $1.5B | ||
| Q2 25 | $436.8M | $1.5B | ||
| Q1 25 | $418.6M | $1.5B | ||
| Q4 24 | $403.7M | $1.4B | ||
| Q3 24 | $405.9M | $1.5B | ||
| Q2 24 | $455.8M | $1.4B | ||
| Q1 24 | $452.0M | $1.4B |
| Q4 25 | $1.4B | $2.7B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.3B | $2.4B | ||
| Q1 25 | $1.3B | $2.5B | ||
| Q4 24 | $1.3B | $2.5B | ||
| Q3 24 | $1.3B | $2.5B | ||
| Q2 24 | $920.8M | $2.5B | ||
| Q1 24 | $914.5M | $2.5B |
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | 4.1% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | — | ||
| Q3 25 | $44.1M | $65.3M | ||
| Q2 25 | $75.8M | $52.2M | ||
| Q1 25 | $35.0M | $21.0M | ||
| Q4 24 | $15.9M | $59.4M | ||
| Q3 24 | $12.5M | $54.0M | ||
| Q2 24 | $17.4M | $43.2M | ||
| Q1 24 | $18.3M | $6.3M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | $53.4M | ||
| Q2 25 | $71.8M | $42.3M | ||
| Q1 25 | $32.5M | $13.0M | ||
| Q4 24 | $13.5M | $49.1M | ||
| Q3 24 | $7.7M | $48.3M | ||
| Q2 24 | $13.0M | $38.3M | ||
| Q1 24 | $13.7M | $-1.9M |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | 18.6% | ||
| Q2 25 | 34.0% | 14.7% | ||
| Q1 25 | 16.5% | 4.8% | ||
| Q4 24 | 7.1% | 19.0% | ||
| Q3 24 | 5.2% | 18.5% | ||
| Q2 24 | 9.4% | 14.1% | ||
| Q1 24 | 10.0% | -0.7% |
| Q4 25 | 0.5% | 4.1% | ||
| Q3 25 | 2.7% | 4.2% | ||
| Q2 25 | 1.9% | 3.4% | ||
| Q1 25 | 1.3% | 2.9% | ||
| Q4 24 | 1.3% | 4.0% | ||
| Q3 24 | 3.2% | 2.2% | ||
| Q2 24 | 3.2% | 1.8% | ||
| Q1 24 | 3.3% | 3.2% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 3.02× | ||
| Q2 25 | 8.87× | 1.98× | ||
| Q1 25 | 2.23× | 0.86× | ||
| Q4 24 | — | 4.27× | ||
| Q3 24 | — | 2.73× | ||
| Q2 24 | — | 1.62× | ||
| Q1 24 | 1.00× | 0.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
NPO
| Sealing Technologies Segment | $187.0M | 63% |
| General Industrial | $71.3M | 24% |
| Power Generation | $19.9M | 7% |
| Oiland Gas Market | $15.0M | 5% |
| Semiconductors | $2.2M | 1% |
